Evidence map›Paper›PMID 38385747›Full record

ArticleJCI insight2024

IL-15 reprogramming compensates for NK cell mitochondrial dysfunction in HIV-1 infection.

Elia Moreno-Cubero, Aljawharah Alrubayyi, Stefan Balint, Ane Ogbe, Upkar S Gill, Rebecca Matthews, Sabine Kinloch, Fiona Burns, Sarah L Rowland-Jones, Persephone Borrow and 3 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 20 citations in OpenAlex.

  1. DRP1 depletion protects NK cells from hypoxia-induced dysfunction.Redox report : communications in free radical research · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Arntl deficiency impairs NK cell function by reducing responsiveness to IL-15 and suppressing activation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Immuno-cell metabolic changes in HIV-1 infection.Infectious diseases & immunity · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Elia Moreno-CuberoNuffield Department of Clinical Medicine and.
Aljawharah AlrubayyiNuffield Department of Clinical Medicine and.
Stefan BalintKennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
Ane OgbeNuffield Department of Clinical Medicine and.
Upkar S GillDepartment of Hepatology, Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Rebecca MatthewsInstitute for Global Health UCL, London, United Kingdom.
Sabine KinlochRoyal Free London NHS Foundation Trust, London, United Kingdom.
Fiona BurnsInstitute for Global Health UCL, London, United Kingdom.
Sarah L Rowland-JonesNuffield Department of Clinical Medicine and.
Persephone BorrowNuffield Department of Clinical Medicine and.
Anna SchurichSchool of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
Michael DustinKennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
Dimitra PeppaRoyal Free London NHS Foundation Trust, London, United Kingdom.
Nuffield Health · GBRoyal Free London NHS Foundation Trust · GBUniversity of Oxford · GBKing's College London · GBQueen Mary University of London · GBUniversity College London · GB

Funding

Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4M
Natural killer cell regulation of the germinal center HIV neutralizing antibody responseR01AI147778 · NIAID · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI BRADLEY, TODD CHRISTOPHER · 2020 to 2024
$3.6M
Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradicationR01AI155182 · NIAID · UNIVERSITY OF OXFORD · PI PEPPA, DIMITRA · 2020 to 2024
$1.9M
Natural killer cell regulation of the germinal center HIV neutralizing antibody responseR56AI147778 · NIAID · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI BRADLEY, TODD CHRISTOPHER · 2019 to 2019
$725k
Medical Research Council MR/M008614/1Medical Research Council MR/M008614/2MRF_ MRF-044-0004-F-GILL-C0823NIAID NIH HHS R01 AI147778NIAID NIH HHS R01 AI155182NIAID NIH HHS R56 AI147778NIAID NIH HHS UM1 AI144371Wellcome Trust
6 · The paper itself

Abstract

Dynamic regulation of cellular metabolism is important for maintaining homeostasis and can directly influence immune cell function and differentiation, including NK cell responses. Persistent HIV-1 infection leads to a state of chronic immune activation, NK cell subset redistribution, and progressive NK cell dysregulation. In this study, we examined the metabolic processes that characterize NK cell subsets in HIV-1 infection, including adaptive NK cell subpopulations expressing the activating receptor NKG2C, which expand during chronic infection. These adaptive NK cells exhibit an enhanced metabolic profile in HIV-1- individuals infected with human cytomegalovirus (HCMV). However, the bioenergetic advantage of adaptive CD57+NKG2C+ NK cells is diminished during chronic HIV-1 infection, where NK cells uniformly display reduced oxidative phosphorylation (OXPHOS). Defective OXPHOS was accompanied by increased mitochondrial depolarization, structural alterations, and increased DRP-1 levels promoting fission, suggesting that mitochondrial defects are restricting the metabolic plasticity of NK cell subsets in HIV-1 infection. The metabolic requirement for the NK cell response to receptor stimulation was alleviated upon IL-15 pretreatment, which enhanced mammalian target of rapamycin complex 1 (mTORC1) activity. IL-15 priming enhanced NK cell functionality to anti-CD16 stimulation in HIV-1 infection, representing an effective strategy for pharmacologically boosting NK cell responses.

Indexed as

Cytomegalovirus InfectionsHIV-1HIV InfectionsMitochondrial DiseasesHumansInterleukin-15Killer Cells, NaturalInterleukin-15AIDS/HIVImmunologyMitochondriaNK cells

Identifiers

PMID38385747
PMCPMC11143930
OpenAlexW4392006291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.